Adiponectin and visfatin levels in extremely low birth weight infants; they are also at risk for insulin resistance (original) (raw)

Abstract

The aim of this study was to assess adiponectin, visfatin, HOMA-IR, glucose and triglyceride levels in term, preterm and extremely low birth weight (ELBW) babies. Each of these three groups was subdivided into two groups as small-for-gestational age (SGA), and appropriate-for-gestational age (AGA). 30 term, 30 preterm and 30 extremely low birth weight infants were included into the study. RESULTS: There was no significant difference in term and preterm infants for serum adiponectin, visfatin, and HOMA-IR levels. There were also no significant differences between term and preterm infants for glucose and triglycerides. The serum visfatin, insulin and HOMA-IR levels (p = 0.001, p = 0.001 and p < 0.05, respectively) were higher in ELBW group than preterm group. Comparing the subgroups as SGA and AGA in all main groups, only in ELBW group there were no significant differences in serum adiponectin, visfatin, HOMA-IR and insulin levels. CONCLUSIONS: We suggest that visfatin can be used as an early indicator of insulin resistance. Independent of being SGA, ELBW itself may be a risk factor for insulin resistance. In the follow-up of these babies the risk of obesity, metabolic syndrome and cardiovascular diseases may be increased as in SGA babies.

Loading...

Loading Preview

Sorry, preview is currently unavailable. You can download the paper by clicking the button above.

References (29)

  1. BEARDSALL K, DIDERHOLM BM, DUNGER DB. Insulin and carbohydrate metabolism. Best Pract Res Clin Endocrinol Metab 2008; 22: 41-55.
  2. VAN AERDE JE, WILKE MS, FELDMAN M, et al. Accre- tion of lipid in the fetus and newborn. In: Polin RA, Fox WW, Abman SH, eds. Fetal and Neonatal Physiology. Vol 1. 3rd edn. Philadelphia, Pennsyl- vania, USA: Saunders, 2003: pp. 388-404.
  3. HALL NJ, PETERS M, EATON S, PIERRO A. Hyper- glycemia is associated with increased morbidity and mortality rates in neonates with necrotizing enterocolitis. J Pediatr Surg 2004; 39: 898-901.
  4. HAYS SP, SMITH EO, SUNEHAG AL. Hyperglycemia is a risk factor for early death and morbidity in ex- tremely low bir th-weight infants. Pediatrics 2006;118: 1811-1888.
  5. KAO LS, MORRIS BH, LALLY KP, STEWART CD, HUSEBY V, KENNEDY KA. Hyperglycemia and morbidity and mortality in extremely low birth weight infants. J Perinatol 2006; 26: 730-736.
  6. ERTL T, GYARMATI J, GAÁL V, SZABÓ I. Relationship be- tween hyperglycemia and retinopathy of prematu- rity in very low birth weight infants. Biol Neonate 2006; 89: 56-59.
  7. BLANCO CL, BAILLARGEON JG, MORRISON RL, GONG AK. Hyperglycemia in extremely low birth weight infants in a predominantly Hispanic population and related morbidities. J Perinatol 2006; 26: 737- 741.
  8. FARRAG HM, NAWRATH LM, HEALEY JE, DORCUS EJ, RAPOZA RE, OH W, COWETT RM. Persistent glucose production and greater peripheral sensitivity to in- sulin in the neonate vs. the adult. Am J Physiol 1997; 272: E86-E93.
  9. RIZZA RA, MANDARINO LJ, GERICH JE. Dose-response characteristics for effects of insulin on production and utilization of glucose in man. Am J Physiol 1981; 240: E630-E639.
  10. HALES CN, BARKER DJ, CLARK PM, COX LJ, FALL C, OS- MOND C, WINTER PD. Fetal and infant growth and impaired glucose tolerance at age 64. Br Med J 1991; 303: 1019-1022.
  11. LIHN AS, PEDERSEN SB, RICHELSEN B. Adiponectin: ac- tion, regulation and association to insulin sensitiv- ity. Obes Rev 2005; 6: 13-21.
  12. GIL-CAMPOS M, CANETE R, GIL A. Adiponectin, the missing link in insulin resistance and obesity. Clin Nutr 2004; 23: 963-974.
  13. LIHN AS, PEDERSEN SB, RICHELSEN B. Adiponectin: ac- tion, regulation and association to insulin sensitiv- ity. Obes Rev 2005; 6: 13-21.
  14. WEYER C, FUNAHASHI T, TANAKA S, HOTTA K, MATSUZA- WA Y, PRATLEY RE, TATARANNI PA. Hypoadiponectine- mia in obesity and type 2 diabetes: close associa- tion with insulin resistance and hyperinsulinemia. J Clin Endocrinol Metab 2001; 86: 1930-1935.
  15. PUNTHAKEE Z, DELVIN EE, O'LOUGHLIN J, PARADIS G, LEVY E, PLATT RW, LAMBERT M. Adiponectin, adiposity, and insulin resistance in children and adolescents. J Clin Endocrinol Metab 2006; 91: 2119-2125.
  16. GIL-CAMPOS M, CANETE R, GIL A. Adiponectin, the missing link in insulin resistance and obesity. Clin Nutr 2004; 23: 963-974.
  17. FUKUHARA A, MATSUDA M, NISHIZAWA M, SEGAWA K, TANAKA M, KISHIMOTO K, MATSUKI Y, MURAKAMI M, ICHISAKA T, MURAKAMI H, WATANABE E, TAKAGI T, AKIYOSHI M, OHTSUBO T, KIHARA S, YAMASHITA S, MAK- ISHIMA M, FUNAHASHI T, YAMANAKA S, HIRAMATSU R, MATSUZAWA Y, SHIMOMURA I. Visfatin: a protein se- creted by visceral fat that mimics the effects of in- sulin. Science 2005; 21: 426-430.
  18. HAIDER DG, SCHALLER G, KAPIOTIS S, MAIER C, LUGER A, WOLZT M. The release of the adipocytokine vis- fatin is regulated by glucose and insulin. Dia- betologia 2006; 49: 1909.
  19. MERAL C, CEKMEZ F, PIRGON O, TANJU I A, IPCIOGLU OM, KARADEMIR F, GOCMEN I. The relationship between serum visfatin, adiponectin, and in- sulin sensitivity markers in neonates after birth. J Matern Fet Neonat Med, DOI:10.3 09/ 14767058.2010.482604.
  20. AMINI SB, CATALANO PM, HIRSCH V, MANN LI. An analysis of birth weight by gestational age using a computerized perinatal data base, 1975-1992. Obstet Gynecol 1994; 83: 342-352.
  21. FENTON TR. A new growth chart for preterm ba- bies: Babson and Benda's chart updated with re- cent data and a new format. BMC Pediatr 2003; 3: 13.
  22. MATTHEWS DR, HOSKER JP, RUDENSKI AS, NAYLOR BA, TREACHER DF, TURNER RC. Homeostasis model as- sessment: insulin resistance and β-cell function from fasting plasma glucose and insulin con- centration in man. Diabetologia 1985; 28: 412- 419.
  23. JENSEN CB, STORGAARD H, DELA F, HOLST JJ, MADSBAD S, VAAG AA. Early differential defects of insulin se- cretion and action in 19-year-old Caucasian men who had low birth weight. Diabetes 2002; 51: 1271-1280.
  24. VAAG A. On the pathophysiology of late onset non-insulin dependent diabetes mellitus. Current controversies and new insights. Dan Med Bull 1999; 46: 197-234.
  25. LEIPALA JA, RAIVIO KO, SARNESTO A, PANTELEON A, FELLMAN V. Intrauterine growth restriction and post- natal steroid treatment effects on insulin sensitivi- ty in preterm neonates. J Pediatr 2002; 141: 472- 476.
  26. GRAY IP, COOPER PA, CORY BJ, TOMAN M, CROWTHER NJ. The intrauterine environment is a strong de- terminant of glucose tolerance during the neona- tal period, even in prematurity. J Clin Endocrinol Metab 2002; 87: 4252-4256.
  27. SOTO N, BAZAES RA, PENA V, SALAZAR T, AVILA A, INIGUEZ G, ONG KK, DUNGER DB, MERICQ MV. In- sulin sensitivity and secretion are related to catch-up growth in small-for-gestational-age in- fants at age 1 year: results from a prospective cohor t. J Clin Endocrinol Metab 2003; 88: 3645-3650.
  28. DAIMON M, OIZUMI T, SAITOH T, KAMEDA W, HIRATA A, YAMAGUCHI H, OHNUMA H, IGARASHI M, TOMINAGA M, KATO T; FUNAGATA STUDY. Decreased serum levels of adiponectin are a risk factor for the progression to type 2 diabetes in the Japanese population. The Funagata Study. Diabetes Care 2003; 26: 2015- 2020.
  29. MALAMITSI-PUCHNER A, DESPINA D. BRIANA, BOUTSIK- OU M, KOUSKOUNI E, HASSIAKOS D, GOURGIOTIS D. Perinatal circulating visfatin levels in intrauterine growth restriction. Pediatrics 2007; 6: 1314- 1318.